InflaRx IFRX
NASDAQ IFRX
$2.10 +0.08 (+3.96%)
At close: Aug 21, 2026 · 4:00 PM EDT

InflaRx (IFRX) Profit After Tax (2016 - 2026)

InflaRx (IFRX) posted Profit After Tax of -$6.6 million for Q1 2026, up 45.59% sequentially from -$12.1 million in Q4 2025, and up 26.27% YoY from -$5.2 million in Q1 2025.

InflaRx (IFRX) Profit After Tax (2016 - 2026) Analysis & Trends

InflaRx has reported Profit After Tax for 11 years, with the latest figure at -$6.6 million in Q1 2026.

  • Quarterly Profit After Tax rose 26.27% year-over-year to -$6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.5 million (up 11.56% YoY) and the FY2025 annual result came in at -$51.6 million, down 3.33% from the prior year.
  • Profit After Tax climbed to -$6.6 million in Q1 2026 per IFRX's latest filing, from -$12.1 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $16.4 million in Q2 2025 and troughed at -$11914.8 billion in Q1 2023.
  • A 5-year average of -$700.9 billion and a median of -$8.9 million in 2025 frame the typical range for Profit After Tax.
  • The sharpest annual moves came in 2022 and 2023: Profit After Tax soared 100.0% in 2022, then plunged 75817607.08% in 2023.
  • Over 5 years, Profit After Tax stood at -$18.4 million in 2022, then gained by 6.66% to -$17.2 million in 2023, then surged by 68.47% to -$5.4 million in 2024, then tumbled by 122.51% to -$12.1 million in 2025, then soared by 45.59% to -$6.6 million in 2026.
  • According to Business Quant data, Profit After Tax over the past three periods registered -$6.6 million, -$12.1 million, and -$14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -355.03 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -16.62 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 InflaRx 140.30 Mn -43.96 Mn 2.74 Bn -12.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.57 Mn
Dec 31, 2025 -12.07 Mn
Sep 30, 2025 -14.35 Mn
Jun 30, 2025 16.45 Mn
Mar 31, 2025 -8.90 Mn
Dec 31, 2024 -5.42 Mn
Sep 30, 2024 -19.25 Mn
Jun 30, 2024 14.88 Mn
Mar 31, 2024 -10.52 Mn
Dec 31, 2023 -17.20 Mn
Sep 30, 2023 -8.03 Mn
Jun 30, 2023 8.93 Mn
Mar 31, 2023 -11,914.76 Bn
Dec 31, 2022 -18.43 Mn
Sep 30, 2022 -3.63 Mn
Jun 30, 2022 5.20 Mn
Mar 31, 2022 -15.72 Mn
Dec 31, 2021 -52,199.42 Bn
Sep 30, 2021 -14.22 Mn
Jun 30, 2021 19.52 Mn